Sanofi to acquire Blueprint Medicines for $9.1 billion in rare disease expansion

Reuters

French pharmaceutical giant Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines for $9.1 billion to strengthen its portfolio in rare immunological diseases.

France-based pharmaceutical company Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines Corporation for $9.1 billion, in a strategic move to bolster its presence in rare immunological diseases.

Blueprint, a biopharmaceutical company specializing in systemic mastocytosis (SM) and other KIT-driven diseases, accepted Sanofi’s offer of $129 per share in cash. The offer represents a 27% premium over Blueprint’s last closing price of $101.35 on Friday.

The acquisition includes Ayvakit (avapritinib), a treatment for SM approved in both the U.S. and EU, along with a robust early- and late-stage immunology pipeline.

“Blueprint’s established relationships with allergists, dermatologists, and immunologists are expected to enhance Sanofi’s growing immunology portfolio,” the French company said in a statement.

The transaction is expected to close in the third quarter of 2025, pending regulatory approvals.

As part of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR), entitling them to potential milestone payments of $2 and $4 per CVR based on future achievements.

Blueprint is currently the only company with an approved drug for systemic mastocytosis - a rare disorder caused by excess mast cells - and is also developing next-generation therapies for SM and other immune disorders.

The acquisition marks the largest healthcare M&A deal in Europe so far this year. It follows Sanofi’s recent purchase of Vigil Neuroscience for $470 million last month - the second time the French company has acquired Vigil in 2025, after an initial purchase in January.

Tags

Comments (0)

What is your opinion on this topic?

Leave the first comment